Objective

Over the past few years primary patient-derived 3D cell models (PD3Ds) have evolved into a valuable tool for translational oncology research. In fact, increasing, independent evidence shows that these organoid cultures resemble tumor biology more closely than traditional cell lines. We have established a panel of >200 PD3D cell models, which represents a unique platform for basic and applied cancer research. Ultimately, our goal is to provide clinicians with a method to explore potential therapies in these in vitro models. Here, we present data on the comprehensive profiling of PD3Ds in (1) phenotypic, (2) genetic and (3) proteomic assays.
(1) PD3Ds were cultured in 384w plates and treated them with multi-point single and combined chemotherapy and targeted drugs, followed by cell viability measurements at 72h post-treatment to drug response patterns.
(2) The genetic background of our PD3D cultures was analyzed using panel sequencing, which provided conclusive data on the driver mutations of the individual tumor.
(3) For measuring proteins and their phosphorylation, DigiWest was used to analyse a panel of 122 total and phospho proteins covering a variety of tumor pathways .
Although the translatability of the predictions from our models to clinical outcomes still need to be thoroughly investigated, we see the results of the current PD3D profiling study as a first step towards truly personalized chemotherapies and a more targeted drug development.